Canadian - U.S. Dietary Reference Intakes Working Group
|
Committee, Advisory Group, or Work Group
|
AHRQ, CDC, FDA, OASH
|
NIDDK, OD/ DPCPSI/ ODS
|
2005
|
|
Cancer Diagnostic Devices Interagency Task Force (CD2) - MOU among NCI, FDA, HRSA
|
Committee, Advisory Group, or Work Group
|
FDA, HRSA
|
|
2021
|
|
CCDI Molecular Target Platform
|
Resource Development
|
FDA
|
|
2021
|
|
CCR Vaccine Branch FACS Core
|
Research Initiative
|
FDA
|
NCI
|
|
|
CCR, LGI, Flow Cytometry Core
|
Research Initiative
|
FDA
|
NCI
|
|
|
Cell-Surface Interactions in Pathogenesis
|
Research Initiative
|
FDA
|
NIDCR
|
|
|
Cervical screening guidelines
|
Resource Development
|
CDC, HRSA, FDA
|
|
2019
|
|
Characterize Emerging HIV Strains from Blood Donors and Patients
|
Resource Development
|
FDA
|
NIAID
|
2009
|
|
Clinical and Translational Research Course for PhD Students
|
Training Initiative
|
FDA
|
CC, NCATS, NCI, NHLBI, NIAID, NIDA, NIDCR, NIDDK, NIGMS, NIMH, NINDS
|
2012
|
|
Clinical and Translational Serology Task Force (CTTF)
|
Resource Development
|
CDC, FDA, ASPR
|
NIAID
|
2021
|
|
Clinical Investigator Interagency Working Group for the Development of Antiviral Influenza Therapeutics
|
Committee, Advisory Group, or Work Group
|
CDC, FDA
|
NIAID
|
2009
|
|
Clinical Vocabulary and Standards Development for Meaningful Use of Electronic Medical Records
|
Resource Development
|
CDC, CMS, FDA, ONC
|
NLM
|
2008
|
|
Combating Antibiotic Resistant Bacteria (CARB)
|
Resource Development
|
CDC, FDA
|
NHGRI, NIAID
|
2015
|
|
Combined Exposures and Mixtures Research Program
|
Research Initiative
|
ATSDR, CDC, FDA, OASH
|
NIEHS
|
|
|
Commissioned Corps of the U.S. Public Health Service (USPHS) Oral Health Coordinating Committee (OHCC)
|
Committee, Advisory Group, or Work Group
|
ACF, ACL, AHRQ, CDC, CMS, FDA, OASH, IHS, SAMHSA
|
|
1990
|
|
Computational Toxicology for NIH Medications Discovery
|
Research Initiative
|
FDA
|
NIDA
|
2000
|
|
Computer-aided Diagnosis for Radiology Images
|
Research Initiative
|
FDA
|
CC, OD/ OIR
|
2004
|
|
Coordinating Committee on Research on Women's Health (CCRWH) Sex, Gender, and Intersectionality (SG&I) Innovations Working Group (CCRWH SG&I Innovations WG)
|
Research Initiative
|
FDA, AHRQ, Other
|
OD, NIA, NHLBI, OD/ AoU, NIGMS, NICHD, NCI, NINDS, NIBIB, NCCIH, NIDA
|
2022
|
|
Countering Biothreats IPC on Promoting and Protecting the Bioeconomy
|
Committee, Advisory Group, or Work Group
|
FDA, OS
|
OD/ OSP
|
2019
|
|
Countering Biothreats sub-IPC on Promoting and Protecting the Bioeconomy
|
Committee, Advisory Group, or Work Group
|
FDA, OS
|
OD/ OSP
|
2019
|
|
COVID-19 Therapeutics Interagency Working Group
|
Committee, Advisory Group, or Work Group
|
FDA, CDC
|
NIAID
|
2020
|
|
Critical Path for Rare Neurodegenerative Diseases (CP-RND)
|
Research Initiative
|
FDA
|
|
2022
|
|
CTAC Ad hoc Strategic Planning Working Group (CTAC SPWG)
|
Committee, Advisory Group, or Work Group
|
FDA, CMS
|
|
2019
|
|
CTAC ad hoc Working Group on Streamlining Clinical Trials (CTAC SCTWG)
|
Committee, Advisory Group, or Work Group
|
FDA
|
|
2022
|
|
CURE ID
|
Research Initiative
|
FDA
|
NCATS
|
2013
|
|
|